Metformin therapy and clinical uses
- PMID: 18777488
- DOI: 10.3132/dvdr.2008.027
Metformin therapy and clinical uses
Abstract
Metformin is now established as a first-line antidiabetic therapy for the management of type 2 diabetes. Its early use in treatment algorithms is supported by lack of weight gain, low risk of hypoglycaemia and its mode of action to counter insulin resistance. The drug's anti-atherosclerotic and cardioprotective effects have recently been confirmed in prospective and retrospective studies, and appear to reflect a collection of glucose-independent effects on the vascular endothelium, suppressant effects on glycation, oxidative stress and formation of adhesion molecules, stimulation of fibrinolysis and favourable effects on the lipid profile. Although avoidance of troublesome gastrointestinal tolerability issues requires careful dose titration, the risk of serious adverse events is considered low provided that contra-indications (especially with respect to renal function) are observed. As many of its actions go beyond glucose lowering, emerging evidence indicates potential benefits in other insulin-resistant states and possibly tumour suppression.
Similar articles
-
Metformin: a multitasking medication.Diab Vasc Dis Res. 2008 Sep;5(3):156. doi: 10.3132/dvdr.2008.026. Diab Vasc Dis Res. 2008. PMID: 18777487 No abstract available.
-
Metformin: diamonds are forever.Expert Opin Pharmacother. 2009 Oct;10(15):2395-7. doi: 10.1517/14656560903176453. Expert Opin Pharmacother. 2009. PMID: 19678795
-
Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'.Cardiovasc J Afr. 2007 Sep-Oct;18(5):331-3. Cardiovasc J Afr. 2007. PMID: 17985034 No abstract available.
-
[Oral antidiabetic therapy].Dtsch Med Wochenschr. 2006 Dec;131 Suppl 8:S264-7. doi: 10.1055/s-2006-956287. Dtsch Med Wochenschr. 2006. PMID: 17139584 Review. German.
-
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7. Expert Opin Pharmacother. 2012. PMID: 22397507 Review.
Cited by
-
Metformin pathways: pharmacokinetics and pharmacodynamics.Pharmacogenet Genomics. 2012 Nov;22(11):820-7. doi: 10.1097/FPC.0b013e3283559b22. Pharmacogenet Genomics. 2012. PMID: 22722338 Free PMC article. Review. No abstract available.
-
The immunomodulatory effects of metformin in LPS-induced macrophages: an in vitro study.Inflamm Res. 2024 Feb;73(2):175-181. doi: 10.1007/s00011-023-01827-8. Epub 2023 Dec 13. Inflamm Res. 2024. PMID: 38091014
-
Advances in the treatment of nonalcoholic fatty liver disease.Ther Adv Endocrinol Metab. 2010 Jun;1(3):101-15. doi: 10.1177/2042018810379587. Ther Adv Endocrinol Metab. 2010. PMID: 23148155 Free PMC article.
-
Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation.J Enzyme Inhib Med Chem. 2018 Dec;33(1):1309-1322. doi: 10.1080/14756366.2018.1499627. J Enzyme Inhib Med Chem. 2018. PMID: 30251898 Free PMC article.
-
Metabolic Effects of Metformin in the Failing Heart.Int J Mol Sci. 2018 Sep 21;19(10):2869. doi: 10.3390/ijms19102869. Int J Mol Sci. 2018. PMID: 30248910 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials